Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer
Abstract Objective We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real‐world big data included in The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data, covering most of the clin...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70226 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593664679870464 |
|---|---|
| author | Hikari Miura Hayato Yamamoto Yoshiharu Okuyama Noritaka Ishi Ryuma Tanaka Takuya Oishi Fumiya Yoneyama Tomoko Hamaya Kyo Togashi Naoki Fujita Teppei Okamoto Chikara Ohyama Shingo Hatakeyama |
| author_facet | Hikari Miura Hayato Yamamoto Yoshiharu Okuyama Noritaka Ishi Ryuma Tanaka Takuya Oishi Fumiya Yoneyama Tomoko Hamaya Kyo Togashi Naoki Fujita Teppei Okamoto Chikara Ohyama Shingo Hatakeyama |
| author_sort | Hikari Miura |
| collection | DOAJ |
| description | Abstract Objective We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real‐world big data included in The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data, covering most of the clinical practices throughout Japan. Methods Usage data for outpatient prescriptions from 2016 to 2021 were extracted from the NDB Open Data. Among the 459,610 million tablets/capsules prescribed, prostate cancer‐specific agents (bicalutamide, estramustine phosphate, flutamide, abiraterone, enzalutamide, apalutamide, and darolutamide) were selected to investigate the trends of usage and medical costs. Results In total, 764.8 billion medications were recorded. Among these, standard dose‐adjusted prescriptions for bicalutamide, abiraterone, enzalutamide, apalutamide, darolutamide, and other vintages (estramustine phosphate, flutamide) was 276, 14.2, 18.1, 2.19, 0.34, and 20.3 million, respectively. The usage of ARSI increased significantly from 6.1% in 2016 to 16% in 2021. The medical costs for prostate cancer‐specific agents increased significantly (1.8‐fold) from 2016 to 2021. Despite the limited usage of ARSIs, a majority of the medical costs had been spent on ARSIs. Medical costs associated with ARSIs increased significantly from 59% to 89% (p < 0.001). Conclusion ARSI usage and medical costs associated with prostate cancer increased significantly from 2016 to 2021. Despite the limited use of ARSIs, a considerable proportion of the medical costs for prostate cancer‐specific agents had been spent on ARSIs. |
| format | Article |
| id | doaj-art-174fd402ec39460caac65f0fec95b545 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-174fd402ec39460caac65f0fec95b5452025-01-20T10:51:32ZengWileyCancer Medicine2045-76342024-12-011324n/an/a10.1002/cam4.70226Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancerHikari Miura0Hayato Yamamoto1Yoshiharu Okuyama2Noritaka Ishi3Ryuma Tanaka4Takuya Oishi5Fumiya Yoneyama6Tomoko Hamaya7Kyo Togashi8Naoki Fujita9Teppei Okamoto10Chikara Ohyama11Shingo Hatakeyama12Department of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanDepartment of Advanced Transplant and Regenerative Medicine Hirosaki University School of Medicine Hirosaki JapanDepartment of Urology Hirosaki University School of Medicine Hirosaki JapanAbstract Objective We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real‐world big data included in The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data, covering most of the clinical practices throughout Japan. Methods Usage data for outpatient prescriptions from 2016 to 2021 were extracted from the NDB Open Data. Among the 459,610 million tablets/capsules prescribed, prostate cancer‐specific agents (bicalutamide, estramustine phosphate, flutamide, abiraterone, enzalutamide, apalutamide, and darolutamide) were selected to investigate the trends of usage and medical costs. Results In total, 764.8 billion medications were recorded. Among these, standard dose‐adjusted prescriptions for bicalutamide, abiraterone, enzalutamide, apalutamide, darolutamide, and other vintages (estramustine phosphate, flutamide) was 276, 14.2, 18.1, 2.19, 0.34, and 20.3 million, respectively. The usage of ARSI increased significantly from 6.1% in 2016 to 16% in 2021. The medical costs for prostate cancer‐specific agents increased significantly (1.8‐fold) from 2016 to 2021. Despite the limited usage of ARSIs, a majority of the medical costs had been spent on ARSIs. Medical costs associated with ARSIs increased significantly from 59% to 89% (p < 0.001). Conclusion ARSI usage and medical costs associated with prostate cancer increased significantly from 2016 to 2021. Despite the limited use of ARSIs, a considerable proportion of the medical costs for prostate cancer‐specific agents had been spent on ARSIs.https://doi.org/10.1002/cam4.70226ARSIcostNDBprostate canceruse |
| spellingShingle | Hikari Miura Hayato Yamamoto Yoshiharu Okuyama Noritaka Ishi Ryuma Tanaka Takuya Oishi Fumiya Yoneyama Tomoko Hamaya Kyo Togashi Naoki Fujita Teppei Okamoto Chikara Ohyama Shingo Hatakeyama Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer Cancer Medicine ARSI cost NDB prostate cancer use |
| title | Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer |
| title_full | Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer |
| title_fullStr | Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer |
| title_full_unstemmed | Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer |
| title_short | Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer |
| title_sort | trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer |
| topic | ARSI cost NDB prostate cancer use |
| url | https://doi.org/10.1002/cam4.70226 |
| work_keys_str_mv | AT hikarimiura trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT hayatoyamamoto trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT yoshiharuokuyama trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT noritakaishi trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT ryumatanaka trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT takuyaoishi trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT fumiyayoneyama trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT tomokohamaya trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT kyotogashi trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT naokifujita trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT teppeiokamoto trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT chikaraohyama trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer AT shingohatakeyama trendsinnovelantiandrogenreceptorsignalinhibitoruseandmedicalcostsinprostatecancer |